Seminars in Hematology
Volume 47, Supplement 1 , Pages S1-S4, April 2010

Functional Classification of Peripheral T-Cell Lymphomas as an Approach to Improve Outcome Prediction and Therapy Selection

  • Dan Jones

      Affiliations

    • Corresponding Author InformationAddress correspondence to Dan Jones, MD, PhD, Professor, Hematopathology, 1515 Holcombe Blvd, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030

The University of Texas M.D. Anderson Cancer Center, Houston, TX

Many types of peripheral T-cell lymphoma (PTCL) are currently classified by the World Health Organization (WHO) based on their predominant site of organ involvement (eg, intestinal or cutaneous types). However, this approach and traditional staging scores such as the IPI can provide limited prognostic information, especially in those PTCL types where morbidity and mortality are primarily related to immune dysregulation and cytokine syndromes driven by the lymphoma cells. These “immune participatory” PTCLs (including, commonly, angioimmunoblastic T-cell lymphoma and many extranodal types) can therefore have poor outcomes even at low tumor burdens. For these reasons, a classification that includes functional profiling of the lymphoma cells may add valuable prognostic information. Such data, including cytokine expression patterns and T-cell receptor signaling pathway activation status, whether normal or abnormal, need to be considered in future classification systems, especially when incorpating targeted therapy.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 STATEMENT OF CONFLICT OF INTEREST: Dr Jones has no conflicts of interest to disclose.

PII: S0037-1963(10)00014-4

doi:10.1053/j.seminhematol.2010.01.013

Seminars in Hematology
Volume 47, Supplement 1 , Pages S1-S4, April 2010